Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy with stem cell support in solid tumors

G Spitzer1, F R Dunphy, C E Bowers

  • 1Division of Bone Marrow Transplantation, St. Louis University School of Medicine, Missouri 63110-0250.

Medical Oncology (Northwood, London, England)
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.

Gynecologic oncology·2016
Same author

Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck.

Head and neck pathology·2015
Same author

Microcirculation in hypertensive patients.

Biorheology·2014
Same author

Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes.

Oral oncology·2013
Same author

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

Cancer journal (Sudbury, Mass.)·2009
Same author

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same journal

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.

Medical oncology (Northwood, London, England)·2026
Same journal

Expedited regulatory approval pathways for novel oncology drugs.

Medical oncology (Northwood, London, England)·2026
Same journal

Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.

Medical oncology (Northwood, London, England)·2026
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
See all related articles

High-dose therapy with stem cell support shows promise for long-term survival in various cancers. Further comparative studies are needed to confirm these findings in early-stage patients.

Area of Science:

  • Oncology
  • Cancer Research
  • Hematology

Background:

  • Ongoing studies in metastatic and high-risk breast cancer require careful interpretation due to patient selection.
  • Lesser-developed studies in ovarian cancer, non-seminomatous germ cell tumors, childhood sarcoma, melanoma, and small cell carcinoma show promising early results.

Purpose of the Study:

  • To review current issues and results in metastatic and high-risk cancers.
  • To identify promising outcomes in early-phase studies for various solid tumors.
  • To outline potential comparative studies of high-dose therapy versus conventional therapy.

Main Methods:

  • Review of Phase II studies involving high-dose therapy with peripheral blood stem cell support (PBSC) or autologous bone marrow transplantation (ABMT).
  • Analysis of patient selection criteria and study outcomes.

Related Experiment Videos

  • Identification of potential comparative study designs.

    • Main Results:

    • Phase II studies of high-dose therapy with PBSC or ABMT demonstrate potential for long-term, disease-free survival across a diverse range of solid tumors.
    • Promising outcomes were observed in smaller studies for ovarian cancer, NSGC, childhood sarcoma, melanoma, and small cell carcinoma.

    Conclusions:

    • High-dose therapy with stem cell support shows significant promise for improving long-term survival in various solid tumors.
    • Caution is advised when interpreting results from studies with specific patient selections.
    • Urgent need for comparative studies in early-stage patients to validate these promising outcomes.